Fortanix Introduces New Data Sovereignty Solutions To Help Organizations Meet Evolving Global Data Security and Privacy Requirements
Fortanix® Inc., the data security company and pioneer of Confidential Computing, today announced new capabilities for Fortanix Data Security Manager (DSM) to help public and private organizations address growing data sovereignty requirements globally. Available now, the existing and new features deliver several key capabilities, including support for sovereign cloud, storing keys in sovereign boundaries, anonymization of private data, centralized control to manage access and enforce consistent policies across hybrid and multicloud environments, and more, all delivered via an intuitive user experience.
Organizations around the globe are taking urgent steps to meet strict, complex, and changing data sovereignty regulations. According to a Gartner® report, “Particularly in Europe, but also in other regions, governments are becoming increasingly concerned due to tightening privacy and data protection regulations impacting data sovereignty, data control, technological sovereignty and their dependence on foreign cloud infrastructure providers.”*
Complying with multitude of mandates is a major challenge for organizations, but Fortanix makes it easy for them to ensure compliance over sensitive data, while also bolstering security. The Fortanix flagship DSM offering can be provisioned within customers’ sovereign regions, enabling them to have a dedicated solution that meets regulations in their legislative jurisdictions.
“Data sovereignty goes beyond just where data resides; it is a multi-layered approach that encompasses data security, protection, and privacy. Fortanix’s existing and new capabilities exemplify our commitment to expanding and enhancing DSM to deliver the most advanced data security and privacy solution to organizations around the globe,” said Faiyaz Shahpurwala, chief product and strategy officer at Fortanix. “Security and data teams can now maintain greater international and cross-border security, compliance, and control over their data with a unified platform that is powered by confidential computing and validated by the highest industry certifications.”
“Data sovereignty, data privacy and compliance with regulations such as GDPR and Schrems II are an integral part of our work in behavioral research,” said Raj Jagesar, project lead for the Digital Phenotyping Research Program (Behapp) at the University of Groningen in the Netherlands. “With Fortanix DSM's External Key Manager for Google Cloud, we have full control over our encryption keys not just for compliance purposes, but also to mitigate any security risks related to sensitive personal data.”
Fortanix DSM’s key data sovereignty capabilities include:
- Full control over key generation and lifecycle management for hybrid, multicloud environments with natively integrated KMS and FIPS 140-2 Level 3 HSM
- The ability to store encryption keys separate from data and within sovereign regions
- Enforced least privileged data access with RBAC and Quorum Controls to support Zero Trust architecture
- Crypto agility with rapid migration to latest approved quantum-proof cryptographic algorithms
- Format-preserving encryption to anonymize sensitive data at ingestion or creation before sharing across pipelines and workflows to keep it private, usable, and compliant
- Native database encryption to manage and store the keys required to encrypt all databases, including Oracle, SQL Server, MongoDB, PostGres, MySQL, Maria DB, IBM DB2, and more
- Joint VMware and Fortanix solution for scalable data protection and compliance for VMware Sovereign cloud environments
- Sovereign support for Google Cloud services/offerings in the Kingdom of Saudi Arabia, in partnership with SITE and CNTXT
- Confidential data search, enabling users to quickly search for regulated data in encrypted databases at terabyte scale
- Customer choice of deployment models: on-premises, virtual appliances running in private or public cloud, or a fully managed SaaS across multiple global regions
Fortanix Expands Client-Side Encryption to Gmail
Fortanix has added support for client-side encryption of Gmail messages, rounding out its offering as an external key manager for organizations working in the Google Workspace ecosystem. This means that data will never be sent from a knowledge worker end point such as an employee laptop without it being encrypted while in transit, boosting data privacy and security across the organization.
Fortanix now offers key management for all Google Workspace applications that use client-side encryption, including Docs, Sheets, Calendar, and now Gmail. This enables Fortanix customers who use Google Workspace to create, store, and manage encryption keys themselves, and not through Google.
Meet with Fortanix at it-sa Expo&Congress 2023
Fortanix will once again have a presence at it-sa Expo&Congress 2023, Europe's largest trade event for IT security. The event takes place Oct. 10-12 at Exhibition Centre Nuremberg in Nuremberg, Germany. Fortanix team members will be on hand in Hall 7, booth number 7-627.
For more information and to purchase tickets, visit the it-sa Expo&Congress website.
Additional Resources
- Download the Fortanix Data Security Manager brief
- Read about Fortanix client-side encryption for Google Workspace
- Explore the programming for it-sa Expo&Congress 2023
About Fortanix
Fortanix secures data, wherever it is. Fortanix’s data-first approach helps businesses of all sizes to modernize their security solutions on-premises, in the cloud, and everywhere in between. Enterprises worldwide, especially in privacy-sensitive industries like healthcare, fintech, financial services, government, and retail, trust Fortanix for data security, privacy and compliance. Fortanix investors include Goldman Sachs, Foundation Capital, Intel Capital, In-Q-Tel, Neotribe Ventures and GiantLeap Capital. Fortanix is headquartered in Santa Clara, CA. For more information, visit https://www.fortanix.com.
*Gartner, What Are the Different Provider Approaches to ‘Sovereign Cloud’ Demands?, Rene Buest, Gregor Petri, Neville Cannon, Bart Willemsen, 4 April 2022
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231010355406/en/
Contact information
BOCA Communications for Fortanix
Fortanix@bocacommunications.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release
Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release
ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom